Skip to main content
Caplight Logo









AltruBio

AltruBio

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://altrubio.com/altrubio/en

Last Round

Series B

May 21, 2024

Total Funding Raised

$288M

Company Overview

AltruBio is a clinical-stage biotechnology company that develops novel antibody therapeutics for immunological and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyimmunologyimmune checkpoint modulatorsulcerative colitisbiopharmaclinical-stage biotechagonist antibodytherapeutic antibodyautoimmune diseasedrug developmentclinical trialsprecision medicineimmunomodulatorsdrug pipelinebiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AltruBio Comparables

Compare AltruBio with similar companies based on industry and business-model similarity.

AltruBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
78%
Athos Therapeutics
77%
AnaptysBio, Inc.
77%

AltruBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 21, 2024
Series AApr 15, 2021
VC RoundAug 15, 2014
VC RoundJun 22, 2012

Key People

Founding team and executive leadership

Judy Chou

President, Chief Executive Officer, And Board Member

Executive Team

AltruBio Investors

Notable investors and investment history

AltruBio investors
InvestorRounds
Soleus CapitalSeries B
RA Capital ManagementSeries B
CAM CapitalSeries A
aMoonSeries B, Series A
BVF Partners L.P.Series A
Blackstone Multi-Asset InvestingSeries B
Blackstone FundsSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 21, 2024

    $225M round with participation from Blackstone Funds and aMoon.

AltruBio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AltruBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AltruBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range29
Year Founded2000
Last FundingMay 21, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?